Compile Data Set for Download or QSAR
Report error Found 79 for UniProtKB: P30279
TargetG1/S-specific cyclin-D2(Human)
University of Nebraska Medical Center

Curated by ChEMBL
LigandPNGBDBM6309(8-cyclopentyl-6-acetyl-5-methyl-2-{[5-(piperazin-1...)
Affinity DataIC50: 15nMAssay Description:Inhibition of CDK6/cyclin D2 (unknown origin) expressed in baculovirus infected insect cells using GST-tagged pRB (792 to 928 residues) as substrate ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/2/2018
Entry Details Article
PubMed
TargetG1/S-specific cyclin-D2(Human)
University of Nebraska Medical Center

Curated by ChEMBL
LigandPNGBDBM6309(8-cyclopentyl-6-acetyl-5-methyl-2-{[5-(piperazin-1...)
Affinity DataIC50: 16nMAssay Description:Inhibition of human CDK6/cyclin-D2 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2021
Entry Details Article
PubMed
TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM513484(4-(3,3-diethyl-7-fluoro-2-methyl-3H-indol-5-yl)-5-...)
Affinity DataIC50: 19.8nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464620(CHEMBL4284941 | US11091476, Example 15)
Affinity DataIC50: 26.9nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM513485(1-(2-((4-(3-Ethyl-7-fluoro-2,3-dimethyl-3H-indol-5...)
Affinity DataIC50: 38.5nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464612(CHEMBL4279791 | US11091476, Example 23)
Affinity DataIC50: 50.3nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464610(CHEMBL4279275 | US11091476, Example 35)
Affinity DataIC50: 64nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464608(CHEMBL4278904 | US11091476, Example 19)
Affinity DataIC50: 64.8nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM513483(5-Fluoro-N-(5-(1-methylpiperidin-4-yl)pyridin-2-yl...)
Affinity DataIC50: 73.7nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464628(CHEMBL4284301 | US11091476, Example 24)
Affinity DataIC50: 76.4nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464628(CHEMBL4284301 | US11091476, Example 24)
Affinity DataIC50: 76.4nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464628(CHEMBL4284301 | US11091476, Example 24)
Affinity DataIC50: 76.4nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464631(CHEMBL4288327 | US11091476, Example 29)
Affinity DataIC50: 82.4nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464622(CHEMBL4280423 | US11091476, Example 7)
Affinity DataIC50: 83.8nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464622(CHEMBL4280423 | US11091476, Example 7)
Affinity DataIC50: 83.8nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464622(CHEMBL4280423 | US11091476, Example 7)
Affinity DataIC50: 83.8nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464619(CHEMBL4292139 | US11091476, Example 16)
Affinity DataIC50: 95.7nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464619(CHEMBL4292139 | US11091476, Example 16)
Affinity DataIC50: 95.7nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464619(CHEMBL4292139 | US11091476, Example 16)
Affinity DataIC50: 95.7nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D2(Human)
Swiss Federal Institute of Technology (Eth)

Curated by ChEMBL
LigandPNGBDBM6655(3-(9-oxo-9H-fluoren-4-yl)-1-pyridin-2-ylurea | N-(...)
Affinity DataIC50: 100nMAssay Description:Inhibition of human recombinant CDK4/Cyclin D2 expressed in baculovirus infected insect Sf9 cells using G1 peptide as substrate after 45 mins by Top ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/14/2017
Entry Details Article
PubMed
TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464607(CHEMBL4293340 | US11091476, Example 36)
Affinity DataIC50: 101nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464603(CHEMBL4291541 | US11091476, Example 11)
Affinity DataIC50: 110nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464617(CHEMBL4284737 | US11091476, Example 34)
Affinity DataIC50: 112nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464629(CHEMBL4286823 | US11091476, Example 21)
Affinity DataIC50: 135nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464626(CHEMBL4288134 | US11091476, Example 32)
Affinity DataIC50: 142nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464614(CHEMBL4277525 | US11091476, Example 6)
Affinity DataIC50: 152nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464614(CHEMBL4277525 | US11091476, Example 6)
Affinity DataIC50: 152nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464614(CHEMBL4277525 | US11091476, Example 6)
Affinity DataIC50: 152nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464614(CHEMBL4277525 | US11091476, Example 6)
Affinity DataIC50: 152nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM513486(1-(2-((5-fluoro-4-(7′-fluoro-2′-methyl...)
Affinity DataIC50: 162nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464638(CHEMBL4292616 | US11091476, Example 33)
Affinity DataIC50: 166nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464632(CHEMBL4279832 | US11091476, Example 30)
Affinity DataIC50: 177nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464632(CHEMBL4279832 | US11091476, Example 30)
Affinity DataIC50: 177nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464630(CHEMBL4281514 | US11091476, Example 18)
Affinity DataIC50: 190nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464630(CHEMBL4281514 | US11091476, Example 18)
Affinity DataIC50: 190nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464611(CHEMBL4280895 | US11091476, Example 26)
Affinity DataIC50: 216nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464611(CHEMBL4280895 | US11091476, Example 26)
Affinity DataIC50: 216nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464621(CHEMBL4276993 | US11091476, Example 14)
Affinity DataIC50: 234nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464621(CHEMBL4276993 | US11091476, Example 14)
Affinity DataIC50: 234nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464624(CHEMBL4284768 | US11091476, Example 9)
Affinity DataIC50: 268nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464624(CHEMBL4284768 | US11091476, Example 9)
Affinity DataIC50: 268nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464624(CHEMBL4284768 | US11091476, Example 9)
Affinity DataIC50: 268nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM513489(5-Fluoro-4-(7′-fluoro-2′-methylspiro[c...)
Affinity DataIC50: 269nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50110183(Abemaciclib | LY-2835219 | US10696678, Example LY2...)
Affinity DataIC50: 319nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50110183(Abemaciclib | LY-2835219 | US10696678, Example LY2...)
Affinity DataIC50: 319nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50110183(Abemaciclib | LY-2835219 | US10696678, Example LY2...)
Affinity DataIC50: 319nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50110183(Abemaciclib | LY-2835219 | US10696678, Example LY2...)
Affinity DataIC50: 319nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464633(CHEMBL4285830 | US11091476, Example 13)
Affinity DataIC50: 327nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464633(CHEMBL4285830 | US11091476, Example 13)
Affinity DataIC50: 327nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G1/S-specific cyclin- 2(Human)
Gan & Lee Pharmaceuticals

US Patent
LigandPNGBDBM50464633(CHEMBL4285830 | US11091476, Example 13)
Affinity DataIC50: 327nMAssay Description: 1.2.2 Preparation of kinase solution: Kinase solutions having the concentrations required for each reaction system were prepared from 100 ng/μl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/30/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 79 total ) | Next | Last >>
Jump to: